FAM111B Activators

FAM111B activators include compounds that interfere with the phosphoinositide 3-kinase (PI3K)/AKT pathway, one of the most critical cell signaling systems. These compounds (LY294002, Wortmannin, Quercetin, Dactolisib, Perifosine, PI-103, ZSTK474, Apigenin) inhibit PI3K, a key upstream kinase in the pathway, or AKT, the main downstream effector. By inhibiting these kinases, they prevent the phosphorylation of multiple downstream targets. One such target is FAM111B, the activity of which is enhanced when it is not phosphorylated. Thus, these compounds, through their inhibitory effects on the PI3K/AKT pathway, can enhance the functional activity of FAM111B.

Additional FAM111B activators include compounds that inhibit mTOR (Rapamycin, Dactolisib, PI-103), a kinase that regulates cell growth and protein synthesis, or p70 S6 kinase (AT7867), a downstream target of mTOR. By inhibiting these kinases, these compounds reduce protein synthesis and cell growth. This is beneficial for FAM111B, which is involved in DNA replication and cell cycle progression. Reduced protein synthesis means that there is less competition for resources, allowing FAM111B to function more effectively. Similarly, slower cell growth means that FAM111B has more time to complete its functions. Thus, these compounds, throughtheir inhibitory effects on mTOR or p70 S6 kinase, can enhance the functional activity of FAM111B. Other FAM111B activators include compounds that specifically target AKT (Perifosine, Triciribine, A-443654, AT7867). AKT, a serine/threonine kinase, is a central component of the PI3K/AKT signaling pathway. Inhibition of AKT leads to reduced phosphorylation of its downstream targets. FAM111B, being a target of AKT, experiences enhanced functional activity when AKT is inhibited.